… Read More
RENO, NV / ACCESSWIRE / November 5, 2020 / GoooGreen, Inc. (OTC PINK:GOOO) subsidiary VegasWINNERS, Inc. announces launch of its newly designed www.vegaswinners.com website as the first step to initiate its ambitious revenue & growth plan, aimed to capitalize on the global online gambling market boom.
The redesigned website features a streamlined design and improved functionality. Enriched content areas will help both current and prospective clients realize the value of VegasWINNERS information, data, analysis, guidance, and professional handicapping advice provided by its stable of respected and well-known sports handicappers to aid in their sports gambling decision-making process.
GoooGreen intends to monetize its VegasWINNERS sports handicapping subsidiary with pay-for-play, monthly subscriptions, advertising, sponsorships and online gambling upon the requisite licensing approval.
“VegasWinners CEO Wayne Allyn Root stated, “Our site has undergone a full re-design. For the first time we have gathered an all-star team of sports handicappers all in one place!
… Read More
GoodRx (GDRX) – Get Report shares fell Monday after the online-prescription-shopping platform received four buy ratings and four holds from analysts who initiated ratings on the company.
The bullish analysts see a huge potential customer base for GoodRx, which went public last month. The neutral analysts express concern about valuation, given GoodRx’s 55% surge from its $33 initial-public-offering price.
The Santa Monica, Calif., company’s shares recently traded at $50.55, down 4.7%.
Morgan Stanley analyst Ricky Goldwasser rates GoodRx overweight with a $57 share-price target.
“GoodRx is the largest healthcare-focused Internet platform that provides users access to prescription drug discounts nationwide,” she wrote in a commentary.
“Leveraging its Internet platform and relationships with health-care stakeholders, GoodRx has unbundled traditional pricing mechanism to create a more equitable cash prescription marketplace for consumers filling generic scripts.”
Goldwasser added, “The company is in early phases of expanding into subscription prescription offering, telehealth